Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InhaleRx Limited ( (AU:IRX) ) has shared an announcement.
InhaleRx Limited has disclosed a change in the indirect interests of director Dr Ronald Wise following his participation in the company’s recent entitlement offer. Through beneficiary interests in Sassey Pty Ltd entities, Dr Wise acquired 113,317 fully paid ordinary shares at an issue price of $0.025 per share and 56,659 free attaching unlisted options exercisable at $0.042 expiring on 23 December 2027, increasing his holdings to 2,606,302 shares, 746,736 performance rights, 500,000 unlisted options at $0.12 expiring 7 July 2028, and 56,659 new options. The transaction, which involved no disposals and did not occur during a closed trading period, signals director support for the capital raising and modestly strengthens insider alignment with shareholders.
More about InhaleRx Limited
InhaleRx Limited is an Australian-listed company operating in the healthcare and life sciences sector, focused on the development and commercialisation of therapeutics delivered via inhalation technologies. The company’s activities centre on specialised drug delivery systems intended to improve the efficacy and speed of action of pharmaceutical treatments in targeted markets.
Average Trading Volume: 287,952
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.39M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.